- Home
- Companies
- usa georgia
- cancerous target
Show results for
Refine by
Cancerous Target Suppliers Serving Usa Georgia
32 companies found
based inRockville, MARYLAND (USA)
Since the treatment of our first oncology patient in 2015, AbelZeta has been able to build best-in-class and best-in-disease potential pipeline, leading to the licensing of two CD20-directed autologous CAR-Ts to Janssen Biotech in 2023. Our goal is ...
based inTucson, ARIZONA (USA)
D3Sciences is dedicated to the development of tools for improved tissue sampling to expand cancer diagnosis, therapy specificity, and research. Creating tools to improve tissue sampling for rapid, precise, and cost effective delivery of care to ...
Detecting, Diagnosing and Treating Cancer: To detect, diagnose, and treat internal cancer requires a team of healthcare providers led generally by three specialist physicians: oncologists, radiologists, and pathologists. Upon examining a patient, ...
based inCleveland, OHIO (USA)
Advances in cancer diagnostics have enabled the detection of cancer at its earliest stages when the chances for successful intervention are highest. For many tumors, surgery offers the best option for a cure, with the potential to remove all cancer ...
based inGarching / Munich, GERMANY
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes ...
based inToronto, ONTARIO (CANADA)
Focal Healthcare is a world-class medical device company dedicated to improving the physician and patient experience from prostate cancer diagnosis to treatment. Throughout his career, Chicuong realized that there were many inefficiencies, ...
based inBasel, SWITZERLAND
Nuclidium AG specializes in leveraging the unique properties of copper radionuclides in conjunction with tumor-specific molecules to enhance the precision, performance, and accessibility of targeted radiotherapy and diagnostics. Their proprietary ...
Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating diagnostic and therapeutic pairs designed to optimize the safety and efficacy profile in cancer treatment. These ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
4-1BB mAb-based, tumor antigen targeting bispecific ...
based inSan Diego, CALIFORNIA (USA)
Stelvio Oncology utilizes an image based method of epigenetic markers to develop predictive diagnostics and novel therapeutics for cancer. Stelvio Oncology is developing a personalized approach to glioblastoma treatment. Our team has core ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 ...
based inFoothill Ranch, CALIFORNIA (USA)
TAE Life Sciences (TLS) is a biologically-targeted radiation therapy company focused on developing novel treatments to improve the lives of patients with invasive, recurrent and difficult to treat cancers. Founded in 2017, TLS is the only company ...
Gordon Locher first proposed Boron Neutron Capture Therapy (BNCT) in 1936. Clinical investigation and treatments were first introduced in the USA in the 1950s and showed promising results. Historically, BNCT clinical studies have been carried out ...
based inWoodinville, WASHINGTON (USA)
Cancer Targeted Technology is designing and patenting small molecular weight enzyme inhibitors with unique and exceptional imaging and drug delivery properties. Cancer Targeted Technology (CTT) develops innovative targeted agents for cancer that ...
CTT1057 is an innovative 18F-labeled PET agent for prostate cancer that can be imaged within 2 hours of administration. CTT1057 will specifically and sensitively detect cancer that has escaped from the prostate as well as distant metastatic disease ...
based inPrinceton, NEW JERSEY (USA)
Taiho Oncology, Inc. specializes in the development of orally administered anti-cancer agents and markets these medicines for a range of tumor types in the U.S. Taiho Oncology’s growing pipeline of selectively targeted anti-cancer agents is led by a ...
based inOxford, UNITED KINGDOM
Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer ...
SCIB2 is the second cancer vaccine based on the ImmunoBody® technology and encodes a modified antibody engineered to express the cancer antigen NY-ESO-1. This is a well-characterised and validated ...
based inSan Diego, CALIFORNIA (USA)
At Kura Oncology, we are committed to realizing the promise of precision medicines for the treatment of cancer. The genomics revolution is transforming how we treat cancer. We now understand that a patient’s response to treatment depends in part on ...
With the advent of precision medicines that can target unique molecular or genetic features of a patient’s tumor, the field of oncology has a host of alternatives to one-size-fits-all treatments. This is a major advance over ...
based inLa Jolla, CALIFORNIA (USA)
Avelas is a clinical-stage drug-device company pioneering the field of fluorescence imaging for real-time cancer detection. Avelas is focused on the development and commercialization of pegloprastide (also referred to as “AVB-620”), a novel ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Immatics is developing Adoptive Cell Therapies, which are designed to leverage the power of T cells to actively infiltrate tumor tissue and kill tumor cells in a specific and serial ...
based inWaterside, UNITED KINGDOM
Lightpoint Medical is a technology leader in targeted cancer surgery. We are developing miniaturized imaging and sensing tools for more precise intra-operative cancer detection. Our mission is to improve the lives of people with cancer by ...
An advanced guidance system designed for intracavity radio-guided surgery. The miniaturized SENSEI® probe enables unprecendented dexterity and anatomic reach, expanding the field of view and enabling the quick localization of radioactive ...
based inNewtown, PENNSYLVANIA (USA)
Formely known as Onconova Therapeutics, Inc. Traws Pharma is a clinical stage biopharmaceutical company developing small molecule oral product candidates for respiratory viral diseases and cancer. In the viral respiratory disease space, Traws Pharma ...
Rigosertib is a small molecule that inhibits multiple cellular signaling pathways driving cancer cell growth while having little effect on normal cells. In contrast to many kinase inhibitors, rigosertib does not interact at the ATP binding site, but ...
based inTucson, ARIZONA (USA)
Novel therapeutics are lacking for Brain Cancer. Only four of the 217 FDA-approved oncology medicines are indicated for life-threatening brain cancers. The most recent approval was in 2009 and did not extend life expectancy. Patients deserve better ...
Only 4 of the 217 FDA-approved oncology medicines are indicated for life-threatening brain cancers. The most recent approval was in 2009, but this medicine did not extend life expectancy. Patients deserve better therapies that extend life and ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...